Xenetic Biosciences Announces Public Offering Pricing

Xenetic Biosciences ( (XBIO) ) has provided an announcement.

On October 10, 2025, Xenetic Biosciences, Inc. announced the pricing of an underwritten public offering of 735,000 shares of common stock at $6.12 per share, expected to close on October 14, 2025. The offering, led by Canaccord Genuity LLC, is anticipated to generate approximately $3.9 million in net proceeds, which the company plans to use for working capital, general corporate purposes, and the advancement of its DNase technology. This move is part of Xenetic’s strategy to strengthen its financial position and support its ongoing development efforts in the immuno-oncology field.

Spark’s Take on XBIO Stock

According to Spark, TipRanks’ AI Analyst, XBIO is a Neutral.

Xenetic Biosciences is currently facing substantial financial and operational challenges, as evidenced by its negative profitability and cash flow metrics. The technical analysis further supports a cautious outlook, with bearish indicators across key metrics. Valuation remains a concern due to the lack of earnings. However, the company’s strong equity position and absence of debt offer some stability as it navigates these challenges.

To see Spark’s full report on XBIO stock, click here.

More about Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies to address difficult-to-treat cancers. The company’s DNase platform aims to enhance the effectiveness of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs) involved in cancer progression. Xenetic is currently working on advancing its systemic DNase program as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

Average Trading Volume: 802,687

Technical Sentiment Signal: Buy

Current Market Cap: $8.28M

See more insights into XBIO stock on TipRanks’ Stock Analysis page.